Literature DB >> 24216446

Survival after sorafenib: expect the unexpected.

Richard S Finn1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24216446     DOI： 10.1016/j.jhep.2013.10.031

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  2 in total

1.  Drug development: try and try again.

Authors:  Megan Scudellari
Journal:  Nature       Date:  2014-12-04       Impact factor: 49.962

2.  Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.

Authors:  Lorenza Rimassa; Giovanni Abbadessa; Nicola Personeni; Camillo Porta; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean-Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Enrico N De Toni; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Maria E Lamar; Yunxia Wang; Dale Shuster; Brian E Schwartz; Armando Santoro
Journal:  Oncotarget       Date:  2016-11-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.